AbbVie Signs Patent License with Mylan for Humira Biosimilar
AbbVie will grant Mylan license to launch a biosimilar to AbbVie’s Humira.
On July 17, 2018, AbbVie announced that it signed patent license agreements with Mylan over Mylan’s proposed biosimilar to AbbVie’s Humira (adalimumab). AbbVie’s product made $18.43 billion in 2017 sales.
Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.
According to AbbVie, Mylan's US license will begin on July 31, 2023 and will not be accelerated by the entries of Amgen's or Samsung Bioepis' Humira biosimilar products. Mylan will pay royalties to AbbVie for licensing its Humira patents once Mylan’s biosimilar product is launched. Mylan acknowledges the validity of the licensed patents. AbbVie will make no payments to Mylan.
In September 2017, AbbVie announced a global resolution with Amgen to enter the US on January 31, 2023, and in April 2018, AbbVie announced a similar resolution with Samsung Bioepis to enter the US on June 30, 2023.
Source: AbbVie
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
